Decibel Therapeutics lands $82.2m Series D

Boston-based Decibel Therapeutics, a developer of novel restorative gene therapeutics to treat hearing loss and balance disorders, has raised $82.2 million in Series D financing.

Boston-based Decibel Therapeutics, a developer of novel restorative gene therapeutics to treat hearing loss and balance disorders, has raised $82.2 million in Series D financing. OrbiMed led the round.

Source: Press Release